Zobrazeno 1 - 10
of 60
pro vyhledávání: '"Maria Ornella, Nicoletto"'
Autor:
Maria Ornella Nicoletto, Alessandra Baldoni, Francesco Cavallin, Andrea Grego, Cristina Falci, Margherita Nardin, Enzo Mammano, Eleonora Lai, Valter Torri
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 15 (2023)
Background: The use of PARP inhibitor (PARPi) has shown a considerable benefit in progression-free survival (PFS) in relapsed, platinum-sensitive epithelial ovarian cancer (OC). Objective: Our study aimed to investigate the impact of the last platinu
Externí odkaz:
https://doaj.org/article/9ed58ccb93c04822ab98dc828d26e551
Autor:
Giulia Tasca, Maria Vittoria Dieci, Zora Baretta, Giovanni Faggioni, Marco Montagna, Maria Ornella Nicoletto, Fedro Alessandro Peccatori, Valentina Guarneri, Nicoletta Colombo
Publikováno v:
Frontiers in Oncology, Vol 10 (2020)
PurposeWe aimed to evaluate the clinico-pathological characteristics and survival outcomes of patients with synchronous or metachronous breast cancer (BC) and ovarian cancer (OC).Materials and MethodsPatients with synchronous or metachronous BC and O
Externí odkaz:
https://doaj.org/article/5b6bf68058b4418aa1e756b420136b35
Autor:
Nicoletta Colombo, Federica Tomao, Pierluigi Benedetti Panici, Maria Ornella Nicoletto, Germana Tognon, Alessandra Bologna, Andrea Alberto Lissoni, Andrea DeCensi, Mariateresa Lapresa, Rosanna Mancari, Innocenza Palaia, Giulia Tasca, Francesca Tettamanzi, Maria Francesca Alvisi, Eliana Rulli, Davide Poli, Luciano Carlucci, Valter Torri, Roldano Fossati, Elena Biagioli
Background: Previous findings showed that cediranib-olaparib increased PFS in women with recurrent platinum-sensitive ovarian cancer compared to olaparib alone. Methods: BAROCCO trial randomized 123 patients: 80 mg/m2 paclitaxel weekly up to 24 weeks
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a50894eb2b17531be40c0f3ed8a7a185
http://hdl.handle.net/11573/1643684
http://hdl.handle.net/11573/1643684
Autor:
Domenica Lorusso, Giorgio Valabrega, Simona Scalone, Ugo De Giorgi, Gaia Giannone, Michele Orditura, Stefano Bogliolo, Furio Maggiorotto, Anna Maria Mosconi, G. Artioli, Gennaro Cormio, Emanuela Rossi, Maria Ornella Nicoletto, Ilaria Spagnoletti, Filippo Greco, Sandro Pignata, Sofia Genta, Lucia Borgato, Anila Kardhashi
Publikováno v:
Gynecologic oncology. 161(3)
Objective Around 15% of epithelial ovarian cancer (EOC) patients (pts) harbor a germline BRCA1 or 2 mutation, showing different features than BRCA wild-type pts. The clinical and pathological features of an Italian BRCA mutated EOC cohort were descri
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b1e62744c0842a7d6a84c34f9d6984c0
https://pubmed.ncbi.nlm.nih.gov/33888336
https://pubmed.ncbi.nlm.nih.gov/33888336
Autor:
Ralph Bloomfield, Jacob Korach, Michael Friedlander, Eric Pujade-Lauraine, Tomasz Huzarski, Daniel Eek, Clare L. Scott, Richard T. Penson, Lari Wenzel, Emma Gibbs, Diane Provencher, Florence Joly, Manuel Rodrigues, Felix Hilpert, Kenji Tamura, Val Gebski, Lucy Davies, Andrew R Clamp, David Espinoza, Vanda Salutari, Laura Vidal, Maria Ornella Nicoletto
Publikováno v:
The Lancet Oncology. 19:1126-1134
Summary Background In the phase 3 SOLO2 trial (ENGOT Ov-21), maintenance therapy with olaparib tablets significantly prolonged progression-free survival (primary endpoint) compared with placebo in patients with a germline BRCA1 or BRCA2 (BRCA1/2) mut
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6d57bf6506b1c37050e48650c26852be
https://doi.org/10.1016/s1470-2045(18)30343-7
https://doi.org/10.1016/s1470-2045(18)30343-7
Autor:
Francesco Perrone, Maria Ornella Nicoletto, Francesco Raspagliesi, Lucia Cannella, Giovanni Scambia, Enrico Breda, Sabrina Chiara Cecere, Giuseppa Maltese, Gennaro Daniele, Alessandra Baldoni, Irene Floriani, Simona Signoriello, Sandro Pignata, Germana Tognon, Nicoletta Colombo, Stefano Greggi, Giovanni Lo Re, Domenica Lorusso, Gabriella Ferrandina, Vanda Salutari, Alice Bergamini, G. Artioli, Maria Carmela Piccirillo
Publikováno v:
Gynecologic Oncology. 144:256-259
Background Few data are available on the outcome of surgery after a bevacizumab-containing regimen. The MITO 16A- MaNGO OV2A phase 4 trial evaluates the outcomes of first-line CPB in a clinical-practice-like setting. Here we present the results of th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::05c58a9cfcc8877b19c166132c948ead
https://doi.org/10.1016/j.ygyno.2016.12.011
https://doi.org/10.1016/j.ygyno.2016.12.011
Autor:
Anna Pastò, Maria Ornella Nicoletto, Elena Laura Mazzoldi, Simona Frezzini, Stefano Indraccolo, Sonia Minuzzo, Giorgia Pilotto, Ilaria Piga, Pietro Palumbo, Massimo Carella, Alberto Amadori
Publikováno v:
Journal of Clinical Medicine
Journal of Clinical Medicine, Vol 9, Iss 2, p 368 (2020)
Journal of Clinical Medicine, Vol 9, Iss 2, p 368 (2020)
The classical cancer stem cell (CSC) model places CSCs at the apex of a hierarchical scale, suggesting different genetic alterations in non-CSCs compared to CSCs, since an ill-defined number of cell generations and time intervals separate CSCs from t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f867c014cd4955705c03bff0040f6d51
http://europepmc.org/articles/PMC7073612
http://europepmc.org/articles/PMC7073612
Autor:
Kevin Leone, Simona Pavan, Anna Pagotto, Maria Ornella Nicoletto, Simona Frezzini, Elena Laura Mazzoldi, Alberto Amadori, Giorgia Pilotto, Anna Pastò
Publikováno v:
Cell Death & Disease
Cell Death and Disease, Vol 10, Iss 6, Pp 1-13 (2019)
Cell Death and Disease, Vol 10, Iss 6, Pp 1-13 (2019)
Receptors tyrosine kinase (RTK) enable normal and tumor cells to perceive and adapt to stimuli present in the microenvironment. These stimuli, also known as growth factors, are important molecular cues actively supporting cancer stem cell (CSC) self-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3325ead9669a5c987c614ea802765d3f
https://doi.org/10.1038/s41419-019-1656-4
https://doi.org/10.1038/s41419-019-1656-4
Autor:
Giovanni Scambia, Cosimo Sacco, Giorgio Valabrega, Maria Carmela Piccirillo, Antonella Savarese, Pierosandro Tagliaferri, Rossella Lauria, Francesco Perrone, Ugo De Giorgi, Sabrina Chiara Cecere, Marilena Di Napoli, Saverio Cinieri, Gabriella Ferrandina, Ciro Gallo, Giulia Amadio, Maria Ornella Nicoletto, Vanda Salutari, Nicola Normanno, Sandro Pignata, Domenica Lorusso, Simona Losito, Giuseppa Maltese, Gennaro Daniele, Anna Maria Mosconi, Claudia Omarini, Alessandra Sacco, Carmela Pisano, Stefano Greggi, Simona Signoriello, Barbara Kopf, Francesco Raspagliesi
Publikováno v:
Gynecologic oncology. 153(3)
Background Cervical cancer cells often express Epidermal Growth Factor Receptor (EGFR). Cetuximab (CET), an anti-EGFR antibody, can be safely combined with carboplatin (C) and paclitaxel (P), a standard treatment for advanced/recurrent cervical cance
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::66c29034571f92f9389631c3aa0fd021
https://pubmed.ncbi.nlm.nih.gov/30979589
https://pubmed.ncbi.nlm.nih.gov/30979589
Autor:
Gian Luca De Salvo, Angela De Paoli, Anna Pagotto, Chiara Bellio, Anna Pastò, Francesca Ricci, Giovanna Damia, Alberto Amadori, Giorgia Pilotto, Alessandra Baldoni, Stefano Indraccolo, Maria Ornella Nicoletto
Publikováno v:
Oncotarget
// Anna Pasto 1 , Anna Pagotto 1 , Giorgia Pilotto 1 , Angela De Paoli 2 , Gian Luca De Salvo 2 , Alessandra Baldoni 2 , Maria Ornella Nicoletto 2 , Francesca Ricci 3 , Giovanna Damia 3 , Chiara Bellio 1 , Stefano Indraccolo 2, * , Alberto Amadori 1,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::979b3e62650221b94499805172044181
http://europepmc.org/articles/PMC5351643
http://europepmc.org/articles/PMC5351643